Surg-51. Decompressive Hemicraniectomy In High-Grade Glioma Patients: Clinical And Radiographic Outcomes

Maria Diaz,Adela Joanta-Gomez,Mary Welch,Guy McKhann,Michael Sisti,Andrew Lassman
DOI: https://doi.org/10.1093/neuonc/noae165.1130
2024-11-29
Neuro-Oncology
Abstract:BACKGROUNDDecompressive hemicraniectomy (DHC) is an uncommonly needed treatment in high-grade gliomas (HGG), most used for refractory increased intracranial pressure (ICP) from vasogenic edema, mass effect, or related complications. Outcomes and imaging following DHC are not well described. METHODSWe retrospectively identified cases of DHC for HGG at our institution since 2019. RESULTSThree patients with HGG underwent DHC (2 females, ages 39-70) for newly diagnosed (2 patients) or recurrent tumor (1 patient). Causes of increased ICP were tumor/vasogenic edema (2 patients) or abscess (1 patient). Subsequent cranioplasty was performed in 2 patients: at 1.8 months after DHC in one patient, and at 8.6 months in another patient who developed sinking skin flap syndrome (SSFS). SSFS presented as progressive worsening of tumor-related neurologic deficits after completion of radiation therapy with no change in imaging, followed by frank signs of increased ICP 8 months after DHC. Two patients died of disease progression (5.3 months and 9.1 months after DHC), and one patient remains alive at 13.5 months (patient with SSFS; neurologic deficits virtually resolved after cranioplasty repair). Imaging will be described for all patients. CONCLUSIONDHC can be a life-saving intervention in HGG. When feasible, early cranioplasty should be considered to avoid complications, including SSFS, which may present with neurological deficits without corresponding imaging change.
oncology,clinical neurology
What problem does this paper attempt to address?